TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study

Conclusions The 365-day cumulative rate of TS-1 administration in TNBC patients was comparable to that in gastric cancer patients despite previous chemotherapy with anthracyclines and/or taxanes. TAT was feasible for TNBC patients after standard primary therapy.

http://link.springer.com/10.1007/s10637-019-00829-w

Source: Investigational New Drugs - July 9, 2019 Category: Drugs & Pharmacology Source Type: research